Phase II trial of mitoxantrone in advanced gastric cancer. 1988

A Goldenberg, and D Kelsen, and P Benedetto
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, N.Y.

A Phase II trial of mitoxantrone was performed in patients with advanced adenocarcinoma of the stomach. All patients had measurable or evaluable disease, and none had received prior chemotherapy. Mitoxantrone was administered intravenously at a dose of 14 mg/m2 every 3 weeks. The major toxicity seen was myelosuppression. The drug was, in general, well tolerated. No major objective responses were seen. We conclude that mitoxantrone has less than 20% activity in this patient population. No further studies are planned.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008942 Mitoxantrone An anthracenedione-derived antineoplastic agent. Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias

Related Publications

A Goldenberg, and D Kelsen, and P Benedetto
November 1982, Cancer treatment reports,
A Goldenberg, and D Kelsen, and P Benedetto
August 1990, Investigational new drugs,
A Goldenberg, and D Kelsen, and P Benedetto
December 1983, Cancer treatment reports,
A Goldenberg, and D Kelsen, and P Benedetto
December 1984, Cancer treatment reports,
A Goldenberg, and D Kelsen, and P Benedetto
January 1983, Cancer treatment reports,
A Goldenberg, and D Kelsen, and P Benedetto
January 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
A Goldenberg, and D Kelsen, and P Benedetto
May 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
A Goldenberg, and D Kelsen, and P Benedetto
April 1996, American journal of clinical oncology,
A Goldenberg, and D Kelsen, and P Benedetto
January 1983, Investigational new drugs,
A Goldenberg, and D Kelsen, and P Benedetto
November 1982, Cancer treatment reports,
Copied contents to your clipboard!